Claris Ventures

Iama Therapeutics specializes in neuroscience drug discovery, aiming to develop innovative medicines for children with brain disorders. Their mission is to improve the lives of these children and provide support to their families.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Resalis Therapeutics focuses on treating metabolic diseases by targeting key regulators of pathways related to obesity and fatty liver disease. Its flagship program, RES-010, is a non-coding RNA drug modality designed for long-term weight loss and reduced hepatic steatosis.

ALKemist Bio specializes in developing cellular immunotherapies focused on targeting ALK-positive cancer cells via engineered T-cell receptors. Their platform involves extracting, modifying, and reinfusing T cells from patients to treat specific oncogene-driven malignancies, aiming to enhance patient outcomes in oncology.

Repron Therapeutics is a healthcare technology company focused on developing innovative treatments for solid tumors that cannot be completely removed through surgery, particularly in cases where there is a high risk of metastasis or recurrence. The company employs engineered synthetic factors to inhibit the activity of oncogenes associated with tumor malignancy. By targeting epigenetic silencing regulations, Repron Therapeutics aims to intercept and eliminate residual tumor cells at the primary site or micro-metastases in specific organs, providing patients with new therapeutic options in challenging cancer cases.

Resalis Therapeutics focuses on treating metabolic diseases by targeting key regulators of pathways related to obesity and fatty liver disease. Its flagship program, RES-010, is a non-coding RNA drug modality designed for long-term weight loss and reduced hepatic steatosis.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

Kither Biotech, established in 2011 and based in Turin, Italy, specializes in researching and developing drugs targeting pulmonary diseases with unmet medical needs. Its primary focus is on two internally developed compounds: KIT2014, a peptide currently in pre-clinical development for treating cystic fibrosis, which has received orphan drug designation from the EMA; and CL27, a molecule intended for chronic obstructive pulmonary diseases and allergic asthma, also in its pre-clinical phase.

Resalis Therapeutics focuses on treating metabolic diseases by targeting key regulators of pathways related to obesity and fatty liver disease. Its flagship program, RES-010, is a non-coding RNA drug modality designed for long-term weight loss and reduced hepatic steatosis.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Kither Biotech, established in 2011 and based in Turin, Italy, specializes in researching and developing drugs targeting pulmonary diseases with unmet medical needs. Its primary focus is on two internally developed compounds: KIT2014, a peptide currently in pre-clinical development for treating cystic fibrosis, which has received orphan drug designation from the EMA; and CL27, a molecule intended for chronic obstructive pulmonary diseases and allergic asthma, also in its pre-clinical phase.

Lever Bio is a biotechnology company focused on developing next-generation immuno-oncology therapies. It collaborates with top researchers, universities, and research centers to accelerate the creation of innovative treatments that enhance the body's immune response against cancer. The company's approach involves reprogramming the metabolic and immune systems to overcome resistance to existing cancer treatments, with a particular focus on solid tumors. This work aims to improve patient outcomes by increasing the recruitment, activation, and sustained function of cytotoxic T lymphocytes.